Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide
- PMID: 9137079
- PMCID: PMC1858209
Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide
Abstract
Activation of the classical pathway in Alzheimer's disease derives from the binding of the first protein, subcomponent C1q, to the amyloid beta-peptide (A beta). Analysis of the binding of C1q to A beta by competitive enzyme-linked immunosorbent assay shows that A beta fragments 1-16 and 1-28 but not 12-28 and 17-42 are capable of inhibiting the A beta/C1q interaction, implicating the A beta 1-11 region as the C1q binding site. Binding is also shown to be inhibited by conditions of high ionic strength, suggesting that charged side chains in the A beta 1-11 region are critical to the A beta/c1q interaction. Ultrastructural evidence of binding is provided by platinum replica electron microscopy. Along with a previous demonstration of the 14-26 region of the C1q A chain as the A beta binding site, these findings suggest that attractions between a negative charge cluster in A beta 1-11 and a positive charge cluster in C1qA14-26 mediate the binding of A beta and C1q.
Similar articles
-
Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation.Biochem Biophys Res Commun. 1995 Dec 26;217(3):869-75. doi: 10.1006/bbrc.1995.2852. Biochem Biophys Res Commun. 1995. PMID: 8554610
-
Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions.J Immunol. 2001 Dec 1;167(11):6374-81. doi: 10.4049/jimmunol.167.11.6374. J Immunol. 2001. PMID: 11714802
-
Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.Clin Exp Immunol. 1999 Mar;115(3):526-33. doi: 10.1046/j.1365-2249.1999.00835.x. Clin Exp Immunol. 1999. PMID: 10193429 Free PMC article.
-
Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease.Res Immunol. 1992 Jul-Aug;143(6):624-30. doi: 10.1016/0923-2494(92)80046-n. Res Immunol. 1992. PMID: 1455054 Review. No abstract available.
-
New insights into the molecular mechanisms of classical complement activation.Mol Immunol. 2010 Aug;47(13):2154-60. doi: 10.1016/j.molimm.2010.05.011. Epub 2010 Jun 9. Mol Immunol. 2010. PMID: 20542571 Review.
Cited by
-
Islet amyloid polypeptide triggers limited complement activation and binds complement inhibitor C4b-binding protein, which enhances fibril formation.J Biol Chem. 2012 Mar 30;287(14):10824-33. doi: 10.1074/jbc.M111.244285. Epub 2012 Feb 13. J Biol Chem. 2012. PMID: 22334700 Free PMC article.
-
Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology.Mol Neurodegener. 2021 Aug 28;16(1):59. doi: 10.1186/s13024-021-00465-0. Mol Neurodegener. 2021. PMID: 34454574 Free PMC article. Review.
-
Innate immunity and neuroinflammation.Mediators Inflamm. 2013;2013:342931. doi: 10.1155/2013/342931. Epub 2013 Jun 15. Mediators Inflamm. 2013. PMID: 23843682 Free PMC article. Review.
-
Complement C7 is a novel risk gene for Alzheimer's disease in Han Chinese.Natl Sci Rev. 2019 Mar;6(2):257-274. doi: 10.1093/nsr/nwy127. Epub 2018 Nov 5. Natl Sci Rev. 2019. PMID: 31032141 Free PMC article.
-
Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.Curr Alzheimer Res. 2017;14(11):1164-1181. doi: 10.2174/1567205014666170508121031. Curr Alzheimer Res. 2017. PMID: 28482786 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical